Anti-Rejection Drugs for Specialty Drugs: Global Market
Anti-Rejection Drugs for Specialty Drugs: Global Market predicts steady growth for the high-value products through 2018.
Pharmaceutical companies continue to pursue the blockbuster drug that will boost their market shares and profit margins. The companies are identifying which anti-rejection drugs can be adapted across lines of use beyond transplantation and into specialty conditions with potential growth opportunities.
“Novartis is a prime example of a company that has capitalized on the trend,” states Norma Corbitt, a senior analyst with more than 25 years experience in pharmaceutical market research. “Expanding everolimus into oncology has netted the company a blockbuster product, Afinitor/Votubia. The product has also propelled mTOR inhibitors, which had been a relatively small market, to the forefront, passing up antimetabolites in sales and gaining on calcineurin inhibitors.”
The Global Market for Fixed-Dose Combination Drugs
Fixed-dose combination drugs have been used for some time in certain therapeutic categories such as antihypertensives, although they were often reserved for second- or third-line therapy. With the revolution in the survival rates of patients suffering from human immunodeficiency virus (HIV) infection that occurred with the implementation of fixed-drug combination products for this, this delivery technology received a boost of confidence as well as an influx of creative applications to other diseases. For the past several years, a number of fixed-dose combination drugs have been introduced for a variety of diseases, some for the first time in a particular disease category.With this in mind, this STIX Market Research report focuses on the impact of fixed-dose combination drug technology on various therapeutic categories, as well as providing assessments and projections of this technology overall and the impact on the patient compliance and effectiveness.. Specifically the aim of this report is to provide a range of information - from detailed market analyses through industry trends - to quantify and qualify the market for fixed-dose combination drugs for the treatment of selected major diseases. Forecasts and trends are gleaned from industry sources as well as from considered assessment of available and emerging technologies. The report develops forecasts for selected disease categories of the fixed-dose combination drug market from 2012 through 2017 and examines strategies employed by biotechnology companies and pharmaceutical firms to develop and market products in this market sector.
STIX is a consulting and information evaluation organization of experts with experience in advanced technology market analysis and identification of business opportunities. The variety of disciplines in the STIX play book include energy, batteries, fuel cells, advanced materials, nanotechnology, alternative fuels and transportation and membrane technologies.
STIX provides factual evaluations of technologies, profiles of companies in the selected market sector, and advice on acquisitions, transitional business opportunities and due diligence. Start-ups, established companies and government entities will find our services of value.
Copyright 2014 STIX Market Research, All Rights Reserved